{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:01:58Z","timestamp":1785438118829,"version":"3.56.0"},"reference-count":23,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>\n                    The treatment setting influences acute myeloid leukemia (AML) outcomes. Most cancer patients receive care in the community, yet few studies have evaluated the effectiveness of clinical programs outside of academic or National Cancer Institute (NCI)-designated cancer centers. This was a multi-level, case-controlled study of real-world outcomes for initial AML treatment in a community-based network for 1,391 patients with AML between 2011 and 2018. We benchmarked survival within our network against the Surveillance, Epidemiology, and End Results (SEER) database. Coarsened exact matching was performed against 17,186 chemotherapy-treated patients in the SEER database. Cox proportional and accelerated failure time multivariable modeling were performed to identify patient, disease, therapy and center characteristics associated with the risk of AML mortality. Within the network, 799 patients were treated at six specialized blood cancer centers and 592 at 63 other hospitals. Patients receiving high-intensity induction at specialized centers had improved median survivals of 31 months versus 18 months [P&lt;0.001] at non-specialized centers. Median survivals were 13 for non-specialized centers versus 10 months for SEER [P&lt;0.001], and 18 for the entire network versus 10 months for SEER [P&lt;0.001]. Multivariable modeling showed significant impacts from age (\n                    <jats:italic>HR<\/jats:italic>\n                    = 1.025), high-intensity induction therapy (\n                    <jats:italic>HR<\/jats:italic>\n                    = .695), diagnosis year (\n                    <jats:italic>HR<\/jats:italic>\n                    = .937), neighborhood income (\n                    <jats:italic>HR<\/jats:italic>\n                    = .997; P&lt;0.01), higher acuity (\n                    <jats:italic>HR<\/jats:italic>\n                    = 1.002) and Charlson comorbidity score (\n                    <jats:italic>HR<\/jats:italic>\n                    = 1.117).\n                  <\/jats:p>\n                  <jats:p>AML treatment may be effectively delivered in the community hospital setting, with specialized centers producing better outcomes for higher intensity treatments.<\/jats:p>","DOI":"10.46989\/001c.124273","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T05:06:42Z","timestamp":1728450402000},"source":"Crossref","is-referenced-by-count":3,"title":["Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting"],"prefix":"10.46989","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6440-1899","authenticated-orcid":false,"given":"Minoo","family":"Battiwalla","sequence":"first","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"name":"Sarah Cannon Center for Blood Cancer at TriStar Centennial"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hsien","family":"Chao","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"name":"Texas Transplant Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Cox","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Carlos","family":"Cruz","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"name":"Texas Transplant Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Donnellan","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"id":[{"id":"https:\/\/ror.org\/03754ky26","id-type":"ROR","asserted-by":"publisher"}],"name":"Tennessee Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Eghtedar","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"id":[{"id":"https:\/\/ror.org\/040pncp85","id-type":"ROR","asserted-by":"publisher"}],"name":"Colorado Blood Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kambhampati","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"name":"HCA Midwest Health at Research Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz","family":"Malik","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"name":"Texas Transplant Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Maris","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"id":[{"id":"https:\/\/ror.org\/040pncp85","id-type":"ROR","asserted-by":"publisher"}],"name":"Colorado Blood Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rotta","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"id":[{"id":"https:\/\/ror.org\/040pncp85","id-type":"ROR","asserted-by":"publisher"}],"name":"Colorado Blood Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank T.","family":"Slovick","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"name":"HCA Midwest Health at Research Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"name":"St. David\u2019s South Austin Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Bhushan","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"id":[{"id":"https:\/\/ror.org\/059rc1n32","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical City Dallas Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Sears","sequence":"additional","affiliation":[{"name":"Healthcare Corporations of America Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Martin","sequence":"additional","affiliation":[{"name":"Healthcare Corporations of America Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Holder","sequence":"additional","affiliation":[{"name":"Healthcare Corporations of America Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Junglen","sequence":"additional","affiliation":[{"name":"Healthcare Corporations of America Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Majhail","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"LeMaistre","sequence":"additional","affiliation":[{"name":"Sarah Cannon Blood Cancer Network"},{"name":"Sarah Cannon Center for Blood Cancer at TriStar Centennial"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"issue":"21","key":"ref1","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1182\/blood-2015-01-625764","article-title":"Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study","volume":"125","author":"S. Giri","year":"2015","journal-title":"Blood"},{"issue":"9","key":"ref2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/cncr.31296","article-title":"Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California","volume":"124","author":"G. Ho","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"ref3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/bjh.14631","article-title":"Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia","volume":"177","author":"G. Ho","year":"2017","journal-title":"Br J Haematol"},{"issue":"19","key":"ref4","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1002\/cncr.30139","article-title":"Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina","volume":"122","author":"A. T. Freeman","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2016-05-716662","article-title":"Hospital volume and acute myeloid leukemia mortality in Medicare beneficiaries aged 65 years and older","volume":"128","author":"M. P. Thompson","year":"2016","journal-title":"Blood"},{"issue":"10","key":"ref6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaoncol.2017.0762","article-title":"The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population","volume":"3","author":"J. M. Unger","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ajh.24246","article-title":"Acute myeloid leukemia--major progress over four decades and glimpses into the future","volume":"91","author":"H. Kantarjian","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"ref8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"M. E. Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"ref9","author":"IRS","year":"2017","unstructured":"18. IRS, 2017. https:\/\/www.irs.gov\/pub\/irs-soi\/17zpallnoagi.csv Accessed July 28, 2019."},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/pan\/mpr013","article-title":"Causal Inference Without Balance Checking: Coarsened Exact Matching","volume":"20","author":"S. M. Iacus","year":"2012","journal-title":"Political Analysis"},{"key":"ref11","article-title":"Cancer Statistics Review, 1975-2016","author":"SEER"},{"issue":"9","key":"ref12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3324\/haematol.2011.040592","article-title":"Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD","volume":"96","author":"H. J. de Jonge","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1756-9966-27-74","article-title":"Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: Cox proportional hazard versus accelerated failure time models","volume":"27","author":"K. Sayehmiri","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood.2020006252","article-title":"Neighborhood-Poverty and Pediatric Allogeneic Hematopoietic Cell Transplantation Outcomes: A CIBMTR Analysis","volume":"137","author":"K. Bona","year":"2021","journal-title":"Blood"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/pop.2011.0104","article-title":"Exploring robust methods for evaluating treatment and comparison groups in chronic care management programs","volume":"16","author":"A. R. Wells","year":"2013","journal-title":"Popul Health Manag"},{"issue":"5","key":"ref16","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"D. Grimwade","year":"2001","journal-title":"Blood"},{"issue":"18","key":"ref17","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"G. Juliusson","year":"2009","journal-title":"Blood"},{"issue":"8","key":"ref18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ajh.24767","article-title":"Early mortality and overall survival of acute myeloid leukemia based on facility type","volume":"92","author":"V. R. Bhatt","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"ref19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/ejh.12841","article-title":"The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia","volume":"98","author":"A.T. Fathi","year":"2017","journal-title":"Eur J Haematol"},{"issue":"11","key":"ref20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.clml.2016.08.006","article-title":"An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices","volume":"16","author":"E. Ma","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"S1","key":"ref21","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2019-124236","article-title":"Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients","volume":"134","author":"L. Ding","year":"2019","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.canep.2016.07.007","article-title":"Socioeconomic status (SES) and childhood acute myeloid leukemia (AML) mortality risk: Analysis of SEER data","volume":"44","author":"N. B. Knoble","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"17","key":"ref23","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"G. Juliusson","year":"2012","journal-title":"Blood"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/124273-determinants-of-outcomes-for-acute-myeloid-leukemia-patients-treated-in-a-community-based-specialized-versus-non-specialized-hospital-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:41:52Z","timestamp":1784734912000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/124273-determinants-of-outcomes-for-acute-myeloid-leukemia-patients-treated-in-a-community-based-specialized-versus-non-specialized-hospital-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.124273","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]}}}